n acetylcysteine glutathione precursor The Central Nervous System Modulatory Activities of N-Acetylcysteine: A Synthesis of Two Decades of Evidence NAC N-Acetyl-L-Cysteine

Values presented as percentage of total Adverse events are presented for all participants who were randomised and took at least one dose of treatment, regardless of whether they discontinued * For the T2D trial, this was limited to supraventricular arrhythmias and cardiac conduction disorders ** For the obesity trial these are presented as hepatic disorder / biliary disorder separately NA : Not applicable In the obesity trial, serious adverse events (SAEs) occurred in 4% of participants with retatrutide use overall (06% across groups) vs

This is unknown and potentially dangerous

The peptide is synthesised and dispatched from our own UK facility rather than imported or repackaged

Initial changes may appear within 4-8 weeks, with optimal results visible after completing the full course of treatment